Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

Gynecologic Oncology

Volumn 130, Issue 3, 2013, Pages 416-420

  Smith, B ^a   Cohn, D E ^a   Clements, A ^a   Tierney, B J ^a   Straughn, J M ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adjuvant chemotherapy; Cervical cancer; Cost effectiveness analysis

Indexed keywords

CISPLATIN; GEMCITABINE;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ANEMIA; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG FATALITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; UTERINE CERVIX CANCER;

EID: 84882453745     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.024     Document Type: Article

References (21)

1. A.D. Dueñas-González, J.J. Zarba, F. Patel, J.C. Alcedo, S. Beslija, and L. Casanova Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix J Clin Oncol 29 13 2011 1678 1685
2. World Health Organization GLOBOCAN 2008 (IARC) Section of Cancer Information Fast Stats: less developed regions, most frequent cancers: women 2008 International Agency for Research on Cancer [ www.who.int/ reproductivehealth/topics/cancer/en ]
3. K. Kinsella, and W. He An aging world: 2008 international population reports http://www.census.gov/prod/2009pubs/p95-09-1.pdf June 2009
4. D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study J Clin Oncol 22 15 2004 3113 3119
5. D.H. Moore Combined chemotherapy and radiation therapy for cervical cancer J Natl Compr Canc Netw 2 6 2004 631 635
6. B.J. Monk, M.W. Sill, D.S. McMeekin, D.E. Cohn, L.M. Ramondetta, and C.H. Boardman Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 27 28 2009 4649 4655
7. A.D. Dueñas-González, L. Cetina, J. Coronel, and D. Martínez-Baños Pharmacotherapy options for locally advanced and advanced cervical cancer Drugs 70 4 2010 403 432
8. K.S. Tewari, and B.J. Monk Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group Semin Oncol 36 2009 170 180
9. G.A. Omura Progress in gynecologic cancer research: the Gynecologic Oncology Group experience Semin Oncol 35 5 2008 507 521
10. Medicare Part B Competitive Acquisition Program (CAP) 2006 drugs and payment amounts, Bioscrip, Inc. VIN: Q103 2006
11. D.E. Cohn, K.H. Kim, K.E. Resnick, D.M. O'Malley, and J.M. Straughn At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis J Clin Oncol 29 10 2011 1247 1251
12. E.A. Calhoun, C.H. Chang, E.E. Welshman, D.A. Fishman, J.R. Lurain, and C.L. Bennett Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients Oncologist 6 2001 441 445
13. G.H. Lyman, and N.M. Kuderer The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia Crit Rev Oncol Hematol 50 2004 129 146
14. S.Y. Liou, J.M. Stephens, K.T. Carpiuc, W. Feng, M.F. Botteman, and J.W. Hay Economic burden of haematological adverse effects in cancer patients Clin Drug Investig 27 6 2007 381 396
15. G.H. Lyman, E.R. Berndt, J.D. Kallich, M.H. Erder, W.H. Crown, and S.R. Long The economic burden of anemia in cancer patients receiving chemotherapy Value Health 8 2 2005 149 156
16. A. Shander, A. Hofmann, S. Ozawa, O.M. Theusinger, H. Gombotz, and D.R. Spahn Activity-based costs of blood transfusions in surgical patients at four hospitals Transfusion 50 2010 753 765
17. World Health Organization World Health Statistics 2011 2011 World Health Organization Geneva [ www.who.int/gho/publications/world-health-statistics/2011/ en/index.html ]
18. Centers for Medicare and Medicaid Services National Health Expenditure data: NHE fact sheet www.cms.gov/Research-Statistics-Data-and-Systems/ Statistics-Trends-and-Reports/NationalHealthExpendData 2008
19. N.T. Phippen, C.A. Leath, J.P. Chino, E.L. Jewell, L.J. Havrilesky, and J.C. Barnett Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix Gynecol Oncol 127 2 2012 267 272
20. H.G. Eichler, S.X. Kong, W.C. Gerth, P. Mavros, and B. Jönsson Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7 5 2004 518 528
21. Centers for Disease Control and Prevention HPV vaccine information for young women - fact sheet http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-young- women.html 2012